CorMedix Inc (NASDAQ:CRMD – Free Report) – Equities research analysts at HC Wainwright boosted their Q3 2026 earnings estimates for CorMedix in a research report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.08) for the quarter, up from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is $0.47 per share. HC Wainwright also issued estimates for CorMedix’s Q4 2026 earnings at ($0.06) EPS.
A number of other equities research analysts have also recently weighed in on the stock. Citizens Jmp reiterated a “market outperform” rating and set a $19.00 price target on shares of CorMedix in a research report on Tuesday, April 28th. Royal Bank Of Canada reiterated an “outperform” rating and set a $14.00 price target (up from $13.00) on shares of CorMedix in a research report on Tuesday, April 28th. Zacks Research upgraded shares of CorMedix from a “strong sell” rating to a “hold” rating in a research report on Friday. Needham & Company LLC lifted their price target on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Finally, Leerink Partners lifted their price target on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, CorMedix has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.
CorMedix Price Performance
CorMedix stock opened at $7.91 on Tuesday. CorMedix has a 12-month low of $6.13 and a 12-month high of $17.43. The stock has a market cap of $620.48 million, a P/E ratio of 3.71 and a beta of 1.46. The company has a 50-day moving average price of $7.13 and a 200 day moving average price of $8.62. The company has a current ratio of 2.97, a quick ratio of 2.74 and a debt-to-equity ratio of 0.33.
CorMedix (NASDAQ:CRMD – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.08. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The firm had revenue of $127.43 million during the quarter, compared to analysts’ expectations of $104.96 million. During the same period last year, the business earned $0.30 earnings per share. CorMedix’s revenue was up 226.1% compared to the same quarter last year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Amundi purchased a new position in shares of CorMedix in the first quarter valued at approximately $132,000. Empowered Funds LLC grew its holdings in CorMedix by 102.1% during the 1st quarter. Empowered Funds LLC now owns 266,637 shares of the company’s stock worth $1,810,000 after acquiring an additional 134,733 shares in the last quarter. Quantinno Capital Management LP grew its holdings in CorMedix by 1,006.4% during the 1st quarter. Quantinno Capital Management LP now owns 124,909 shares of the company’s stock worth $848,000 after acquiring an additional 113,619 shares in the last quarter. Royal Capital Wealth Management LLC acquired a new position in CorMedix during the 1st quarter worth approximately $194,000. Finally, American Financial Advisors LLC grew its holdings in CorMedix by 29.4% during the 1st quarter. American Financial Advisors LLC now owns 64,757 shares of the company’s stock worth $440,000 after acquiring an additional 14,700 shares in the last quarter. Hedge funds and other institutional investors own 34.18% of the company’s stock.
CorMedix declared that its board has approved a stock repurchase program on Monday, February 2nd that permits the company to buyback $75.00 million in shares. This buyback authorization permits the company to reacquire up to 12.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.
CorMedix Company Profile
CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.
In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.
Read More
- Five stocks we like better than CorMedix
- Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade?
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
